NCT05521698View on ClinicalTrials.gov

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

July 15, 2027

Conditions
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
DRUG

Apalutamide

Given PO

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

DRUG

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Transurethral Resection of Bladder Tumor

Undergo TURBT

Trial Locations (6)

14642

University of Rochester, Rochester

20892

National Cancer Institute Urologic Oncology Branch, Bethesda

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

85719

University of Arizona Cancer Center - Prevention Research Clinic, Tucson

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH